Regeneron

Why can a first dose of gene therapy sometimes make a second dose  harder to deliver? The immune system can learn to recognize the adeno- associated virus (AAV) delivery vehicle from the first dose, and attack it before it delivers the therapy the next time. Our scientists challenged that assumption, studying how the immune system responds to AAV at its most fundamental level. What they found: a role for CD40, a protein central to activating immune responses, and a promising path toward AAV re-dosing.    Watch how our scientists are tackling this roadblock: https://bit.ly/4fZ96cw

Our teams bridge drug discovery and manufacturing, and we know the secret recipe for turning scientific breakthroughs into real-world therapies. 🔬🍪    As Angela Hill, Senior Staff Engineer, explains to “Science Simplifier” Logan, the challenge isn't just baking one perfect batch. It’s creating a repeatable, scalable process that delivers the same result every time! Grab a fresh batch of insights in the latest #TechTrailblazers episode here: https://bit.ly/4wfcRkc

Placebo controls are an important way to evaluate potential medicines, but their use is not mandatory.    Participant safety is always the priority in any clinical trial, so not all #ClinicalTrials use placebo controls. The use of a placebo depends on the disease and trial design.     Learn more at https://lnkd.in/e7BncvjG 

Our new paper in Nature highlights how human genetics can help uncover potential new therapeutic strategies for obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and broader cardiometabolic disease.💡 Regeneron Genetics Center researchers combined exome data from more than one million people with studies in human liver cells and animal models to investigate the FNIP1 pathway's role in energy metabolism. The findings identify the pathway as a potential therapeutic target and demonstrate how large-scale human genetics can help prioritize new approaches to disease. Read the full paper: https://bit.ly/4q04TKa #HumanGenetics #Genomics #CardiometabolicDisease

Yesterday was #NationalInternDay, and we celebrated in style with games, outdoor fun, and plenty of laughs from around the globe. Our 650+ interns have spent their summer diving headfirst into work that matters. This crew shows up ready to learn, ask sharp questions, and make a real impact across teams, time zones, and disciplines. To our interns, and everyone who helped build another standout global program this year — thank you. Check out the photos below from yesterday’s celebration and join us in giving our incredible interns a shoutout in the comments!

Join us in congratulating the 2026 winners 2026 Regeneron Prize for Creative Innovation! This year recognizes Simon Vecchioni, Ph.D. (New York University), Siyuan Du, Ph.D. (Stanford University) and Frank Peters (Rensselaer Polytechnic Institute) for their bold ideas presented in 'dream project' proposals. Established in 2013, the Regeneron Prize is part of our STEM-Fueled™ commitment to the next generation of scientific leaders. Winners are nominated by their research universities and selected by a panel of our scientists for scientific merit, originality and creativity. “The Regeneron Prize exists because of a simple but profound truth that I’ve lived firsthand: behind every scientist who changes the world, there are people who believed in them first,” said George Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. Meet this year’s winners. 👉 https://bit.ly/4vXCbuM #STEMFueled

Today we reported strong financial results from the second quarter of 2026, with total revenues up 17% compared to the second quarter of 2025 and all-time quarterly net sale highs for three key products. We carry this momentum into the second half of the year, as we continue to pursue our mission of translating science into medicine for people around the world. Q2 2026 and Recent Highlights 🧠 Regulatory applications under review by the FDA and EMA for our investigational treatment for generalized myasthenia gravis (gMG) ✅ Pipeline progress across hematology, ophthalmology, rare diseases and metabolic diseases 🤝 Entered a strategic collaboration with Parabilis Medicines to advance a novel class of antibody-peptide conjugates across multiple therapeutic areas 🌟 Recognized for responsibility leadership by the Dow Jones Best-in-Class World Index and Points of Light's Civic 50, naming the most community-minded companies in the U.S. Thank you to our colleagues, collaborators, investigators and patients who make it all happen. Read more: https://bit.ly/4h0JApi

We are deeply saddened by the passing of financial industry luminary and Regeneron’s longtime director, Arthur “Art” Ryan. Art served on our Board of Directors for more than two decades and was a trusted advisor whose judgment, integrity, and business insight helped guide the company through many important milestones. We will miss his wisdom and unwavering support of Regeneron's mission. Prior to joining Regeneron's Board, Art built a distinguished career in financial services, including serving as Chairman and Chief Executive Officer of Prudential Financial and as President and Chief Operating Officer of Chase Manhattan Bank. Art also left an enduring legacy of civic engagement and philanthropy throughout Newark and Essex County, New Jersey. On behalf of everyone at Regeneron, we are grateful for Art's many contributions and years of service. We join his family, and all who knew him, in celebrating his life and legacy.

Now live: the MCPS Imputation Server, a free research resource built on sequencing data generated by Regeneron Genetics Center and developed in collaboration with the Universidad Nacional Autónoma de México (UNAM) and Oxford Population Health. The platform enables researchers worldwide to impute genetic variants using data from the Mexico City Prospective Study, the largest genetic study of a Latin American population, helping address longstanding gaps in genomic representation. Jonathan Marchini of Regeneron Genetics Center, Professor Jaime Berumen of UNAM and Dr. Jason Torres of Oxford Population Health share perspectives on the collaboration and the science behind the platform. Read more: https://bit.ly/3TPiVSD 

What can people who are naturally protected from disease teach us about developing new medicines? At Regeneron Genetics Center (RGC), researchers search for the rare 'superhumans' whose genetics may reveal protective factors hidden in human biology. After more than a decade of studying these signals at scale, RGC has uncovered more than 100 compelling genetic stories, and translated ~50 of them into potential medicines across Regeneron’s pipeline. Aris Baras, M.D., Senior Vice President and Head of Regeneron Genetics Center, joined host Ben Comer on the Business of Biotech podcast to discuss how these discoveries are helping drive innovation. 🎧 Listen to the conversation: http://bit.ly/3THHbpP #GeneticResearch #Genetics #PrecisionMedicine